Enterprise Value to EBITDA Ratio: Accuray Incorporated (ARAY)
Accuray Incorporated (ARAY) is developing a business focused on creating robotic systems for tumor treatment, relying on a balance between equipment deliveries and long-term maintenance. Due to the uniqueness of its products, the company consistently exports equipment, as evidenced in the pakistan asset value chart, where the indicator stands at 9.26. However, trade barriers and sanctions in several regions may limit service support and reduce revenues.
Metric breakdowns and analytics for accuray.com (ARAY)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
ARAY - Final Profit|Projected Future Earnings Accuray Incorporated|ARAY - P/E Multiple|Projected Price to Earnings Accuray Incorporated|ARAY - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Accuray, Inc.|ARAY - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Accuray Incorporated|ARAY - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months accuray.com|ARAY - Earnings per share growth this year|Earnings growth forecast for next year Accuray Incorporated
Analysis of all company metrics:Accuray Inc. ARAY
This indicator determines the real value of a business, excluding the impact of capital structure and tax obligations. Analyzing the EV/EBITDA ratio for a capital-intensive business allows for the identification of a gap between market price and operational efficiency. The metric compares the total value of the company with its earnings before depreciation and interest. For Accuray Incorporated (ARAY), this is critical, as the cost of CyberKnife systems and service contracts requires significant capital expenditures.
Competitors of Accuray Incorporated (ARAY)
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple ERAS|EV/EBITDA Multiple delcath.com (DCTH)|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|AURA - Enterprise Value to EBITDA Ratio|Candel - EV/EBITDA Multiple|SELLAS Life Sciences (SLS) - Enterprise Value to EBITDA Ratio|ACTU (Actuate Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|citiusonc.com (CTOR) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TuHURA Biosciences Inc.|TARA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple FATE|EV/EBITDA Multiple aadibio.com (WHWK)|TScan Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Champions Oncology Inc (CSBR) - Company Value to EBITDA|XBIT: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CVM (CEL-SCI Corporation)|OSTX: EV/EBITDA Multiple|RADX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artiva Biotherapeutics Inc.|Enterprise Value to Operating Income Before Depreciation ANL (Adlai Nortye Limited)|EV/EBITDA Multiple VERU|Enterprise Value to EBITDA Ratio Tempest Therapeutics Inc TPST|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xilio Therapeutics XLO|Renovaro Biosciences (RENB) - Company Value to EBITDA|MURA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation KAPA (Kairos Pharma Ltd)|onkuretherapeutics.com (OKUR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio GDTC (CytoMed Therapeutics Limited)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Curis Inc.|Company Value to EBITDA Apollomics Corp APLM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tharimmune, Inc. (THAR)|ADVB (advanbiomed.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex)|EV/EBITDA Multiple Calidi Biotherapeutics Inc. CLDI|SBFM: Enterprise Value to EBITDA Ratio|Xenetic Biosciences - Enterprise Value to Operating Income Before Depreciation Ratio|SLRX: EV/EBITDA Multiple|Company Value to EBITDA purple-biotech.com (PPBT)|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation BGNE (BeiGene Ltd.)|EV/EBITDA Multiple CKPT|EV/EBITDA Multiple Elevation Oncology Inc. (ELEV)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iCAD ICAD|Business Value to Operating Income Before Depreciation IKNA|Notable Labs - EV/EBITDA Multiple|VIRX - EV/EBITDA Multiple|MOR (MorphoSys Corp) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA NAYA Biosciences Corp (NAYA)|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
